User menu

Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration

Bibliographic reference Dexter, David T. ; Statton, Sarah A. ; Whitmore, Charlotte ; Freinbichler, Wolfhard ; Weinberger, Peter ; et. al. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. In: Journal of Neural Transmission. General Section, Vol. 118, no. 3, p. 223-231 (2011)
Permanent URL
  1. Avramovich-Tirosh Yael, Amit Tamar, Bar-Am Orit, Zheng Hailin, Fridkin Mati, Youdim Moussa B. H., Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator?monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease, 10.1111/j.1471-4159.2006.04258.x
  2. Ben-Shachar D., Eshel G., Finberg J. P. M., Youdim M. B. H., The Iron Chelator Desferrioxamine (Desferal) Retards 6-Hydroxydopamine-Induced Degeneration of Nigrostriatal Dopamine Neurons, 10.1111/j.1471-4159.1991.tb11444.x
  3. Boddaert N., Le Quan Sang K. H., Rotig A., Leroy-Willig A., Gallet S., Brunelle F., Sidi D., Thalabard J.-C., Munnich A., Cabantchik Z. I., Selective iron chelation in Friedreich ataxia: biologic and clinical implications, 10.1182/blood-2006-12-065433
  4. Cappellini Maria Domenica, Bejaoui Mohamed, Agaoglu Leyla, Porter John, Coates Thomas, Jeng Michael, Lai Maria Eliana, Mangiagli Antonio, Strauss Gabriele, Girot Robert, Watman Nora, Ferster Alina, Loggetto Sandra, Abish Sharon, Cario Holger, Zoumbos Nicolaos, Vichinsky Elliott, Opitz Herbert, Ressayre-Djaffer Catherine, Abetz Linda, Rofail Diana, Baladi Jean-Francois, Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia, 10.1016/j.clinthera.2007.05.007
  5. Carvey P. M., Zhao C. H., Hendey B., Lum H., Trachtenberg J., Desai B. S., Snyder J., Zhu Y. G., Ling Z. D., 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability, 10.1111/j.1460-9568.2005.04281.x
  6. MCLACHLAN D, Intramuscular desferrioxamine in patients with Alzheimer's disease, 10.1016/0140-6736(91)92978-b
  7. Crichton RR, Ward RJ (2006) Metal-based neurodegeneration: from molecular mechanisms to therapeutic perspectives. Wiley, Chichester, pp 21–52
  8. Datla K. P., Bennett R. D., Zbarsky V., Aruoma O. I., Dexter D. T., Ke B., Liang Y.-F., Hig T., Bahorun T., The antioxidant drink “effective microorganism-X (EM-X)” pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease, 10.1211/0022357023222
  9. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., Marsden C.D., INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN, 10.1016/s0140-6736(87)91361-4
  10. Duce James A., Bush Ashley I., Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics, 10.1016/j.pneurobio.2010.04.003
  11. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener. doi: 101186/1750-1326-4-47
  12. Freinbichler Wolfhardt, Colivicchi Maria A., Fattori Manuela, Ballini Chiara, Tipton Keith F., Linert Wolfgang, Della Corte Laura, Validation of a robust and sensitive method for detecting hydroxyl radical formation together with evoked neurotransmitter release in brain microdialysis, 10.1111/j.1471-4159.2007.05168.x
  13. Gerlach M, Double KL, Youdim MB, Riederer P (2006) Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 70:133–42
  14. Halliwell Barry, Role of Free Radicals in the Neurodegenerative Diseases : Therapeutic Implications for Antioxidant Treatment, 10.2165/00002512-200118090-00004
  15. Hanson L. R., Roeytenberg A., Martinez P. M., Coppes V. G., Sweet D. C., Rao R. J., Marti D. L., Hoekman J. D., Matthews R. B., Frey W. H., Panter S. S., Intranasal Deferoxamine Provides Increased Brain Exposure and Significant Protection in Rat Ischemic Stroke, 10.1124/jpet.108.149807
  16. Hua Y, Keep RF, Hoff JT, Xi G (2008) Deferoxamine therapy for intracerebral hemorrhage. Acta Neurochir Suppl 105:3–6
  17. Kakhlon O., Manning H., Breuer W., Melamed-Book N., Lu C., Cortopassi G., Munnich A., Cabantchik Z. I., Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation, 10.1182/blood-2008-06-161919
  18. Liu Gang, Men Ping, Perry George, Smith Mark A., Nanoparticle and Iron Chelators as a Potential Novel Alzheimer Therapy, Methods in Molecular Biology (2010) ISBN:9781588297105 p.123-144, 10.1007/978-1-60327-029-8_8
  19. Markesbery William R., Carney John M., Oxidative Alterations in Alzheimer's Disease, 10.1111/j.1750-3639.1999.tb00215.x
  20. Crapper McLachlan D. R., Smith W. L., Kruck T. P., Desferrioxamine and Alzheimerʼs Disease : Video Home Behavior Assessment of Clinical Course and Measures of Brain Aluminum, 10.1097/00007691-199312000-00027
  21. Mills E, Dong A, Wang F, Xu H (2010) Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med Chem 2(51):1–19
  22. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, Australia
  23. Perez Carlos, Tong Yong, Guo Maolin, Iron Chelators as Potential Therapeutic Agents for Parkinsons Disease, 10.2174/157340708786305952
  24. Polson R J, Jawed A, Bomford A, Berry H, Williams R, Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects., 10.1136/bmj.291.6493.448
  25. Praticò Domenico, Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal, 10.1016/
  26. Selim M., Deferoxamine Mesylate: A New Hope for Intracerebral Hemorrhage: From Bench to Clinical Trials, 10.1161/strokeaha.108.533125
  27. Shachar Dorit Ben, Kahana Nava, Kampel Vladimir, Warshawsky Abraham, Youdim Moussa B.H, Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats, 10.1016/j.neuropharm.2003.09.005
  28. Smith M. A., Harris P. L. R., Sayre L. M., Perry G., Iron accumulation in Alzheimer disease is a source of redox-generated free radicals, 10.1073/pnas.94.18.9866
  29. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G. P., Hebenstreit G., Youdim M. B. H., Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain, 10.1007/bf01244786
  30. Stankiewicz James M, Brass Steven D, Role of iron in neurotoxicity: a cause for concern in the elderly? : , 10.1097/mco.0b013e32831ba07c
  31. Vernon Anthony C., Zbarsky Virginia, Datla Krishna P., Croucher Martin J., Dexter David T., Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo, 10.1111/j.1471-4159.2007.04860.x
  32. Wang, J, Jiang, H, Xie, JX (2007) Ferroportin 1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur J Neurosci 25:2766–2772
  33. Ward Roberta J., Dexter David, Florence Anne, Aouad Fouad, Hider Robert, Jenner Peter, Crichton Robert R., Brain iron in the ferrocene-loaded rat: Its chelation and influence on dopamine metabolism, 10.1016/0006-2952(94)00521-m
  34. Ward Roberta J., Colivicchi Maria Alessandra, Allen Rachel, Schol François, Lallemand Frédéric, de Witte Philippe, Ballini Chiara, Corte Laura Della, Dexter David, Neuro-inflammation induced in the hippocampus of ‘binge drinking’ rats may be mediated by elevated extracellular glutamate content, 10.1111/j.1471-4159.2009.06389.x
  35. Weinreb Orly, Amit Tamar, Mandel Silvia, Kupershmidt Lana, Youdim Moussa B.H., Neuroprotective Multifunctional Iron Chelators: From Redox-Sensitive Process to Novel Therapeutic Opportunities, 10.1089/ars.2009.2929
  36. YOUDIM MOUSSA B. H., STEPHENSON GALIA, SHACHAR DORIT BEN, Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6-Hydroxydopamine and Iron Chelators, Desferal and VK-28, 10.1196/annals.1306.025
  37. Carman LS, Gage FH, Shults CW (1991) Partial lesion of the substantia nigra: relation between extent of lesion and rotational behaviour. Brain Res 553:275–283